Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, Protagonist Therapeutics (PTGX) has a market cap of $2.88 billion USD. According to our data, Protagonist Therapeutics is ranked No.3414 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $2.88 B |
25.28%
|
| Dec 31, 2024 | $2.30 B |
68.34%
|
| Dec 29, 2023 | $1.37 B |
110.17%
|
| Dec 30, 2022 | $0.65 B |
-68.10%
|
| Dec 31, 2021 | $2.04 B |
69.64%
|
| Dec 31, 2020 | $1.20 B |
185.96%
|
| Dec 31, 2019 | $0.42 B |
4.75%
|
| Dec 31, 2018 | $0.40 B |
-67.64%
|
| Dec 29, 2017 | $1.24 B |
-5.41%
|
| Dec 30, 2016 | $1.31 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Moderna
MRNA
|
$10.14 B |
-0.001 M
|
USA
|
 Alnylam Pharmaceuticals
ALNY
|
$29.89 B |
-0.001 M
|
USA
|
 Ionis Pharmaceuticals
IONS
|
$4.51 B |
0.000 M
|
USA
|
 Sarepta Therapeutics
SRPT
|
$5.28 B |
-0.000 M
|
USA
|
 bluebird bio
BLUE
|
$43.76 M |
0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.34 B |
0.000 M
|
Switzerland
|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$0.76 B |
-0.000 M
|
USA
|
 Beam Therapeutics
BEAM
|
$1.73 B |
0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.17 B |
0.000 M
|
USA
|
| Market Cap | = | PTGX Stock Price | * | PTGX Shares Outstanding |
| = | $46.95 | * | 61.38 M | |
| = | $2.88 B |